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Leukoencephalopathy with vanishing white matter, also called “childhood ataxia with central nervous system
hypomyelination,” is the first human disease related to mutations in any of the five genes encoding subunits of
eukaryotic initiation factor eIF2B or any translation factor at all. eIF2B is essential in all cells of the body for
protein synthesis and the regulation of this protein synthesis under different stress conditions. It is surprising that
mutations in the eIF2B genes have been reported to lead to abnormalities of the white matter of the brain only,
although it has been shown recently that ovarian failure may accompany the leukoencephalopathy. Another sur-
prising observation is that the onset of the disease varies from early childhood to adulthood, with the exception
of Cree leukoencephalopathy, a disease related to a particular mutation in one of the eIF2B genes, which invariably
has its onset within the first year of life. We analyzed the eIF2B genes of nine patients with an antenatal- or early-
infantile–onset encephalopathy and an early demise and found mutations in eight of the patients. In addition to
signs of a serious encephalopathy, we found oligohydramnios, intrauterine growth retardation, cataracts, pancre-
atitis, hepatosplenomegaly, hypoplasia of the kidneys, and ovarian dysgenesis. Until now, no evidence had been
found for a genotype-phenotype correlation, but the consistently severe phenotype in affected siblings among our
patients and in Cree encephalopathy patients suggests an influence of the genotype on the phenotype.
Translation of mRNA into polypeptides is one of the
major energy-consuming processes in the cell and is
therefore, not surprisingly, a tightly regulated process
(Proud 2002). The initiation phase, in which ribosomes
are assembled on mRNA, is controlled via several dif-
ferent signaling pathways (Kleijn et al. 1998). Multiple
eukaryotic initiation factors (eIFs) are involved in trans-
lation initiation, and, among them, the guanine-nucle-
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otide-exchange factor eIF2B plays a key regulatory role
(Proud 2001). A crucial step in translation initiation is
the delivery by eIF2 of the initiator methionyl-transfer
RNA (Met-tRNAi) to the small ribosomal subunit. Upon
recognition of the start codon, the eIF2-bound guanosine
triphosphate (GTP) is hydrolyzed, and eIF2 is released
in its inactive guanosine diphosphate (GDP)–bound
form. To bind another Met-tRNAi, active eIF2 must be
regenerated by the exchange of GDP for GTP. This step
is catalyzed by eIF2B. The exchange of GDP for GTP
by eIF2B is required for each round of translation ini-
tiation, and regulation of this step can control global
rates of protein synthesis under diverse conditions (Hin-
nebusch 2000).
Protein synthesis is markedly inhibited under a variety
of stress conditions and in the recovery phase that fol-
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lows. This response is part of a protective mechanism
of cells that is elicited by various stimuli, including phys-
ical, chemical, oxidative, and thermal trauma, called the
“cellular stress response” or “heat shock response”
(Welch 1992). Stress may lead to the misfolding and
denaturation of proteins, contributing to cell dysfunc-
tion and death. The inhibition of normal RNA trans-
lation during stress is thought to enhance cell survival
by limiting the accumulation of denatured proteins and
saving cellular energy.
Inhibition of mRNA translation can be achieved
through the modification of several initiation factors
(Schneider 2000). Most stress conditions, including heat
stress (Duncan and Hershey 1989; Scheper et al. 1997),
lead to activation of specific kinases that phosphorylate
eIF2 on its a-subunit. In this phosphorylated form, eIF2
is a competitive inhibitor of eIF2B, preventing the re-
cycling of eIF2 (Hershey and Merrick 2000). The con-
centration of eIF2 usually exceeds that of eIF2B (Oldfield
et al. 1994). Therefore, even modest levels of eIF2a
phosphorylation can potentially lead to a complete in-
hibition of translation initiation and protein synthesis
(Rowlands et al. 1988; Oldfield et al. 1994). In certain
cell types, inactivation of eIF2B at 40–41C, in the febrile
range for humans, can be achieved without changes in
eIF2a phosphorylation (Scheper et al. 1997). eIF2B ac-
tivity can also be regulated through other pathways,
such as phosphorylation at different sites, which can
enhance or suppress eIF2B activity (Proud 2002).
Whether these pathways are involved in the regulation
of eIF2B activity under stress conditions is unclear.
eIF2B is a protein complex, composed of five noni-
dentical subunits (a–), encoded by five different genes,
EIF2B1–EIF2B5, located on different chromosomes
(12q24.3, 14q24, 1p34.1, 2p23.3, and 3q27, respec-
tively). The essential role of eIF2B, both in normal pro-
tein production and in its regulation under different con-
ditions, including elevated temperature, is reflected by
the evolutionary conservation of the complex (Hershey
and Merrick 2000) and the nonviability of yeast null
mutants for each of the subunits except eIF2Ba (Hin-
nebusch 2000). Considering the indispensability of
eIF2B for normal cell function, it was expected that hu-
man cells bearing two inactivating mutations in one of
the eIF2B subunits would not be viable.
We were surprised to find that vanishing white matter
(VWM [MIM 603896]) (van der Knaap et al. 1997),
also called “childhood ataxia with central nervous sys-
tem hypomyelination” (CACH) (Schiffmann et al.
1994), is caused by mutations in any of the five eIF2B
genes (Leegwater et al. 1999, 2001; van der Knaap et
al. 2002). VWM/CACH is one of the novel leukoence-
phalopathies described in the 1990s (Hanefeld et al.
1993; Schiffmann et al. 1994; van der Knaap et al.
1997). It is one of the most prevalent inherited childhood
white matter disorders (van der Knaap et al. 1999). The
disease is characterized by progressive neurological de-
terioration with cerebellar ataxia, spasticity, and rela-
tively mild mental decline. The disease is chronic pro-
gressive with episodes of major and rapid deterioration
following minor head trauma and especially febrile in-
fections. These episodes may end in unexplained coma.
Death usually follows an episode of coma. If a patient
survives the coma, partial recovery occurs. Magnetic res-
onance imaging (MRI) of the brain shows extensive ce-
rebral white matter changes from the presymptomatic
stage onwards and, over time, evidence of disappearance
of the affected white matter, which is replaced by fluid
(van der Knaap et al. 1997, 1998). This was confirmed
by multiple autopsies, which showed rarefaction and
cystic degeneration of the cerebral white matter (van der
Knaap et al. 1997, 1998; Rodriguez et al. 1999; Wong
et al. 2000; Bru¨ck et al. 2001). MRI shows that VWM/
CACH, in contrast to other cystic leukoencephalopa-
thies, exhibits radiating stripes of preserved tissue
strands within the rarefied and cystic white matter, giving
the images a highly characteristic appearance (van der
Knaap et al. 1997, 1998).
In patients with VWM/CACH, serious deteriorations
often follow febrile infections, which could correlate
with the heat sensitivity of eIF2B. It is surprising that
the disease has been reported to exclusively affect the
white matter of the brain, even though eIF2B is present
and essential for protein synthesis and its regulation in
all cells of the body. Not only are other organs spared
but, within the brain, the cerebral cortex is usually
spared as well (van der Knaap et al. 1997, 1998; Rod-
riguez et al. 1999; Wong et al. 2000; Bru¨ck et al. 2001).
Another surprising observation was that most patients
have a normal initial development and a childhood onset
of clinical symptomatology (Hanefeld et al. 1993; Schiff-
mann et al. 1994; van der Knaap et al. 1997). Adolescent
and adult onsets also have been described (van der
Knaap et al. 1998). Apparently, it is possible to be ho-
mozygous or compound heterozygous for mutations in
any of the eIF2B genes and have normal neurological
function for a period of a few to many years.
Since a DNA-based diagnosis of VWM/CACH is now
available, patients with atypical clinical and MRI find-
ings can be analyzed for mutations in EIF2B1–EIF2B5.
Until now, we had mainly found missense mutations in
typical patients with VWM/CACH (Leegwater et al.
2001; van der Knaap et al. 2002). Major mutations,
which prevent the expression of full-length eIF2B sub-
units, were only observed in the compound-heterozy-
gous state with a missense mutation as second mutation
(Leegwater et al. 2001; van der Knaap et al. 2002). Sev-
eral atypical cases of patients with VWM/CACH or re-
lated disorders suggested that other or more serious mu-
tations might lead to an earlier onset of the disease and
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possibly to involvement of other organs. (1) Two sibling
patients with VWM/CACH were described with an un-
usually early onset at 11 and 10 mo and death at 18
and 13 mo (Fogli et al. 2002a). (2) Cree leukoence-
phalopathy was found to be a variant of VWM/CACH
(Fogli et al. 2002b). The onset of Cree encephalopathy
is between 3 and 9 mo, and death occurs before the age
of 2 years (Black et al. 1988). (3) In 1997, one patient
was described who had VWM/CACH and ovarian dys-
genesis at autopsy (van der Knaap et al. 1997). The co-
occurrence of mutations in the eIF2B genes with a com-
bination of a leukoencephalopathy and ovarian failure
was recently confirmed in a much larger series of pa-
tients, providing the first evidence that mutations in
eIF2B genes can lead to involvement of organs other
than the brain (Fogli et al. 2003).
Considering the cases above, we reasoned that mu-
tations in the eIF2B genes might lead to an earlier onset
of the disease and possibly to involvement of other or-
gans. Following these hypotheses, we decided to perform
DNA analysis in nine patients with an early-onset leu-
koencephalopathy and, in some of them, involvement of
other organs.
Patients 1, 2, and 3 are sisters. The parents are healthy
and unrelated. The mother had two miscarriages, at 9
and 10 wk into pregnancy. There are two healthy chil-
dren. In patient 1, decreased movements and oligohy-
dramnios were noted late in gestation. After birth at 38
wk of gestation, she had some initial difficulties with
hypotonia and a low body temperature. Blood sugars
were just below normal. She had congenital dislocation
of the hips. She was an irritable baby. From the age of
3 mo, she deteriorated, with intractable seizures, feeding
difficulties, hypotonia, apathy, and finally coma and res-
piratory failure. On physical examination, she had he-
patosplenomegaly, oil-droplet cataracts, hypotonia, and
brisk reflexes. A liver biopsy revealed nonspecific ab-
normalities, with markedly increased smooth endo-
plasmic reticulum, decreased glycogen stores, and re-
active Kupffer cells, but otherwise intact architecture.
Patient 1 died at the age of 8 mo. Her affected sisters
had a similar clinical picture and died at 4.5 and 5 mo.
Patients 4 and 5 are the only son and daughter of
healthy, consanguineous parents. Both patients had se-
rious fetal growth retardation, oligohydramnios, and mi-
crocephaly at term birth. The clinical course after birth
was rapidly downhill, with feeding difficulties, vomiting,
apathy, axial hypotonia, hypertonia and hyperreflexia of
the extremities, seizures, and finally apneic events. Ab-
dominal ultrasounds revealed hypoplastic kidneys. The
patients died at 3.5 and 4 mo, respectively.
Patient 6 is the daughter of healthy, unrelated parents.
There are two healthy siblings. She was described in
detail in the work of Boltshauser et al. (2002). Growth
retardation and oligohydramnios were noted at 31 wk
gestational age. Born at 38 wk of gestation, she had
microcephaly, bilateral cataracts, and mild contractures.
The clinical course was dominated by impaired swal-
lowing, failure to thrive, myoclonic convulsions, and ab-
sence of any psychomotor development. Aspiration
pneumonia led to death at 10 mo. An autopsy revealed,
apart from the aspiration pneumonia, mild pancreatitis
and dysgenesis of the ovaries.
Patient 7 is a boy with healthy, unrelated parents. He
has two healthy siblings. He was born at term. At age
5 mo, developmental delay and hypotonia became ap-
parent shortly after a vaccination and an upper respi-
ratory tract infection. The hypotonia gradually changed
into hypertonia with hyperreflexia. He became progres-
sively lethargic and finally lapsed into coma. He died at
age 7 mo because of respiratory insufficiency.
Patient 8 is the son of healthy, consanguineous par-
ents. His sister died of a similar disease at 13 mo. He
has three healthy siblings. He was born at term. At age
6 mo, he developed axial hypotonia and lost head con-
trol. Following a mild febrile illness, he became coma-
tose, with episodes of irregular breathing. He died at age
9 mo.
Patient 9 is a boy, the only child of healthy, unrelated
parents. He was born at term. At the age of 4.5 mo, he
presented symptoms of chronic and episodic neurolog-
ical deterioration. The episodes of rapid deterioration
were provoked by infections. His clinical picture was
dominated by hypotonia and cerebellar ataxia without
spasticity. Following a viral infection with fever, he
lapsed into coma and died at age 25 mo.
In summary, only in patients 7, 8, and 9 was the clin-
ical picture that of typical VWM/CACH, with an epi-
sodic course and exclusive involvement of the brain, al-
though with an earlier onset than usual.
In all patients, extensive routine and metabolic inves-
tigations were performed, which were unrevealing.
MRIs of the brain were obtained at the following ages:
3, 4, and 5 mo in patient 1; 2 d in patient 2; 3 mo in
patients 3 and 4; 1 and 4 mo in patient 5; 6 d and 5
mo in patient 6; 6 mo in patient 7; 9 mo in patient 8;
and 17 and 24 mo in patient 9. All cerebral and cere-
bellar white matter structures had a high signal intensity
on T2-weighted images and a low signal intensity on T1-
weighted images, as would be normal for unmyelinated
white matter (Barkovich et al. 1988; van der Knaap et
al. 1990). However, in all patients except patients 2, 3,
and 6 (first MRIs), the cerebral white matter had a higher
T2 signal intensity than normal for unmyelinated white
matter (fig. 1). The white matter signal intensity became
more abnormal on follow-up (fig. 2). Some cerebral
white matter structures should be myelinated at birth,
but there was no evidence of this in our patients, indi-
cating a defect in myelination (fig. 1). In addition, the
gyri were slightly broader than normal in all patients
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Figure 1 Illustration of the variation in white matter abnormalities in patients with VWM/CACH. For this purpose, T2-weighted and
FLAIR images of patient 3 at 3 mo (A and B, respectively) and patient 7 at 6 mo (C and D, respectively) are shown, as well as T2-weighted
and FLAIR images of a normal infant at 4 mo (E and F, respectively). In patient 3, the transverse T2-weighted image (A) is normal for the age,
except that the progress of myelination is insufficient. The myelin deposition should cause the internal capsule to have a low signal intensity
(arrow in E), but it still has a high signal intensity throughout (arrow in A). The FLAIR image is shown at a slightly higher level, where areas
of low signal intensity are seen within the cerebral white matter, indicative of rarefaction (B). Such areas are not seen on the FLAIR image of
the normal infant (F). In patient 7, the cerebral white matter has too high a signal intensity on the T2-weighted image (C), higher than normal
for unmyelinated white matter (E). The gyri are mildly broadened. The FLAIR image shows that a large part of the white matter has a lower
signal intensity, consistent with rarefaction (D). A subtle stripe-like pattern is visible within the rarefied white matter (D).
except patient 3, indicating delayed gyral development
or slight white matter swelling. Proton density images
and/or fluid-attenuated inversion recovery (FLAIR) im-
ages were obtained in patients 1, 2, 3, 7, 8, and 9. With
the exception of patient 2 at age 2 d, these showed a
lower signal intensity in parts of the cerebral white mat-
ter, although not as low as cerebrospinal fluid, indicative
of white matter rarefaction but not (yet) cystic degen-
eration (fig. 1). Only in patients 7 and 8 did the abnor-
mal white matter have the stripe-like pattern on axial
FLAIR or sagittal T1-weighted images (fig. 1) so typical
of VWM/CACH, and only in these two patients did the
MRI display the classic appearance of VWM/CACH
(van der Knaap et al. 1997, 1998). In patients 1, 2, 3,
and 9, the white matter rarefaction could suggest a di-
agnosis of VWM/CACH, but the typical stripes were
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Figure 2 Illustration of the degree of white matter volume loss. Transverse T2-weighted and sagittal T1-weighted images of patient 6,
obtained at 6 d (A and B, respectively) and 5 mo (C and D, respectively), and transverse T2-weighted and sagittal T1-weighted images of a
normal-term neonate (E and F, respectively) are shown. The first MRI in patient 6, obtained at 6 d, shows broadening of gyri (A) as compared
to the width of gyri in a normal neonate (E). The cerebral white matter has a normal signal intensity for unmyelinated white matter on the
T2-weighted image (compare A and E). The lateral ventricles are mildly dilated. The cerebellar vermis is on the small side (compare B and F).
The T2-weighted image at 5 mo shows that an impressive atrophy of the cerebral white matter has occurred with enormous dilatation of the
lateral ventricles (C). What remains of the white matter now has too high a signal intensity, even for unmyelinated white matter. The sagittal
image shows marked atrophy of the cerebellum (D). Also the pons is flatter than normal. These images are reproduced from the work of
Boltshauser et al. (2002) with permission.
lacking. In patients 5 and 6, the lateral ventricles became
highly dilated because of pronounced white matter at-
rophy (fig. 2), which is not a feature of typical VWM/
CACH (van der Knaap et al. 1997, 1998). They also
had striking atrophy of the cerebellum. In patient 9, the
splenium of the corpus callosum was abnormal and
highly swollen, which has not been reported before in
patients with VWM/CACH. The globus pallidus and
thalamus showed an abnormal signal intensity, which is
also unusual in individuals with VWM/CACH.
We performed mutational analysis of EIF2B1–
EIF2B5 in all nine patients. The exons and flanking in-
tron DNA of the genes under investigation were ampli-
fied by PCR, as described elsewhere (Leegwater et al.
1999, 2001), with oligonucleotide primers whose se-
quences are available on the VU University Medical Cen-
ter Web site. The DNA fragments were subsequently
analyzed by DNA sequencing with BigDye Terminators
on an ABI PRISM 310 Genetic Analyzer (Applied Bios-
ystems) as recommended by the manufacturer.
We found mutations in individual eIF2B genes in pa-
tients 1–8 (table 1). None of the mutations were found
in 210 control chromosomes of individuals of northern
European descent, making it unlikely that they represent
polymorphisms. In agreement with this, these mutations
are not reported in the SNP databases of NCBI and
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Table 1
Genotypic and Phenotypic Data for Eight Patients with eIF2B Gene Mutations
PATIENT GENE SUBUNIT
MUTATION
POSITION
PROTEIN
UNDERGOING
MUTATION STATE
PARENT
CARRYING
ALLELE
ORGANS INVOLVED/
PHENOTYPE
1–3 EIF2B2 eIF2Bb 599GrT
871CrT
G200V
P291S
Heterozygous
Heterozygous
Father
Mother
Brain, lens, liver
4, 5 EIF2B4 eIF2Bd 1447CrT R483W Homozygous Father, mother Brain, kidney, body growth
6 EIF2B4 eIF2Bd 1172CrA A391D Homozygous Father, mother Brain, lens, pancreas, ova-
ries, body growth
7 EIF2B5 eIF2B 1289TrC
1340CrT
V430A
S447L
Heterozygous
Heterozygous
Father
Mother
Brain
8 EIF2B5 EIF2B 1484ArG Y495C Homozygous Father, mother Brain
Celera. The two healthy siblings of patient 7 and the
three healthy siblings of patient 8 were investigated as
well. Three were found to be heterozygous for one mu-
tation; two did not carry any mutation in EIF2B5. All
parents were investigated, and each of them was found
to carry one mutation. Only in patient 9 were we unable
to identify a mutation in one of the five genes. Although
his clinical picture was very suggestive of VWM, his
MRIs showed some features that are atypical for patients
with VWM/CACH.
Formerly, no evidence was found for a genotype-phe-
notype correlation, but the consistently severe phenotype
in affected siblings among our patients and in Cree en-
cephalopathy patients suggests an influence of the ge-
notype on the phenotype.
All mutations observed in patients 1–8 are novel ex-
cept for the Val430Ala mutation in eIF2B (Leegwater
et al. 1999) in patient 7. Most mutations involve highly
conserved amino acids (for two examples, see fig. 3).
The a-, b-, and d-subunits of eIF2B display mutual se-
quence similarity. Alanine at position 391 (Ala391) in
eIF2Bd and Gly200 in eIF2Bb (fig. 3a) are not only gen-
erally conserved in different species but also in the ho-
mologous sequences of the other two subunits, suggest-
ing they are key residues. Arg483 in eIF2Bd is conserved
in mammals only. However, the mutation to tryptophan
(a basic residue replaced by a bulky aromatic amino
acid) is likely to result in a substantial alteration in the
three-dimensional structure of the protein. Valine at po-
sition 430 and serine at position 447 of eIF2B are con-
served in mammals, and nonmammalian species have a
hydrophobic and hydroxy amino acid here, respectively.
The changes of Val430Ala (from a branched-chain
amino acid to a much smaller and less hydrophobic res-
idue) and Ser447Leu (from a small and polar amino acid
to a branched-chain hydrophobic residue) may both lead
to major alterations in the conformation of the protein.
Pro291 in eIF2Bb and Tyr495 in eIF2B are conserved
in all mammals and several nonmammalian species (fig.
3b). Again the changes from the imino acid proline to
the small polar residue serine (in Pro291Ser) and from
tyrosine with an aromatic side chain to the small sul-
phur-containing cysteine (in Tyr495Cys) are likely to af-
fect the (local) structure of the subunit. Thus, our pa-
tients are homozygous or compound-heterozygous for
mutations that are likely to affect markedly the structure
of eIF2B and therefore its function, contributing to the
severe phenotype.
The Arg195His mutation in eIF2B is found in Cree
leukoencephalopathy (Fogli et al. 2002b). Arg195 is
conserved in mammals and the change from an aliphatic
side-chain containing a positively charged guanidino
group to a heterocyclic imidazole group is likely to affect
the conformation of this subunit as well. In contrast, the
drastic effect of the Val309Leu mutation in two severely
affected sibling patients (Fogli et al. 2002a) is unclear.
Both valine and leucine are branched-chain aliphatic
amino acids; branched-chain residues are conserved at
the position corresponding to Val309 in all -subunit
sequences and at the corresponding position in the re-
lated sequence of eIF2Bg. Most strikingly, leucine is pre-
sent at this position in Caenorhabditis elegans eIF2B
and in rat and yeast eIF2Bg.
Some of the earlier-published mutations—for instance,
the mutation that causes the alteration Glu213Gly in
eIF2Bb (Leegwater et al. 1999)—also involve well-con-
served residues, whereas the clinical picture is that of
classic VWM/CACH. It is important to realize that, of
course, not only the nature of the changes caused by the
mutations in both alleles or the conservation of the res-
idues involved but also the position of the changes within
the protein will determine the effect of the mutations on
the activity of the eIF2B complex. However, too little is
known presently about the various functional domains
in the eIF2B subunits to allow correlation of the position
of the mutations with the severity of the disease. None
of the amino acid changes mentioned in table 1 occurs
in the catalytic domain of the -subunit or affects known
phosphorylation sites.
Our findings demonstrate that patients with VWM/
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Figure 3 Examples of conserved residues in eIF2B involved in severe forms of VWM. A, Alignment of the sequence containing Gly200
(box) of human eIF2Bb with corresponding sequences of eIF2Bb of the indicated species and with the corresponding sequences of human eIF2Ba
and eIF2Bd. Residues conserved among all three human subunits and eIF2Bb of all species are indicated in gray. B, Alignment of the region
surrounding Tyr495 in human eIF2B with the corresponding sequences of eIF2B in other species. The conserved tyrosine is indicated by the
box; residues that are conserved in at least five species are indicated in gray.
CACH can have a very early, even antenatal, onset with
decreased fetal movements, retardation of intrauterine
growth, and oligohydramnios, and at birth microceph-
aly and contractures. More importantly, it is clear for
the first time that patients with mutations in eIF2B genes
can suffer from a multisystem disorder with growth re-
tardation, dysgenesis of the ovaries, pancreatic abnor-
malities, hypoplastic kidneys, hepatosplenomegaly, or
cataracts, in addition to the leukoencephalopathy. It is
unlikely that an unrelated disease caused these addi-
tional abnormalities. Most importantly, affected siblings
showed involvement of the same organs, whereas sib-
lings carrying no mutations or only one mutation did
not show signs of any disease.
Whereas mutations in eIF2B subunit genes that cause
VWM/CACH probably lead to decreased eIF2B activity,
a persistent high activity of eIF2B underlies Wolcott-
Rallison syndrome (MIM 226980). This is an exceed-
ingly rare autosomal recessive multisystem disorder
characterized by intrauterine growth retardation, early
infantile permanent diabetes mellitus, multiple epiphys-
eal dysplasia, renal impairment, central hypothyroidism,
developmental delay, and recurrent episodes of hepatic
dysfunction, ascribed to “hepatitis” (Bin-Abbas et al.
2002). The disease is caused by mutations in EIF2AK3
(Dele´pine et al. 2000), also called PEK or PERK, the
gene encoding the enzyme eukaryotic translation initi-
ation factor 2a kinase 3, also called pancreatic eIF2a
kinase (PEK) or PKR-like ER kinase (PERK). PERK is
an endoplasmic-reticulum-resident, transmembrane pro-
tein. It couples stress signals that are initiated by protein
malfolding in the lumen of the endoplasmic reticulum
with phosphorylation of eIF2a, which inhibits the ac-
tivity of eIF2B, resulting in decreased protein synthesis
(Harding et al. 1999, 2000). In patients with Wolcott-
Rallison syndrome, the mutations, where tested, led to
a loss of function of PERK. This presumably results in
persistent high eIF2B activity and consequent inability
to switch off protein synthesis in response to endo-
plasmic reticulum stress. There are evident clinical dif-
ferences between VWM/CACH and Wolcott-Rallison
syndrome, but the two disorders share the inability to
regulate protein synthesis adequately under different
stress conditions.
Although the patients presented here were different
from typical patients with VWM/CACH, they still had
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a leukoencephalopathy. The next, most intriguing ques-
tion is whether it is possible that patients with selective
involvement of other organs without an accompanying
leukoencephalopathy may carry mutations in eIF2B
genes. Episodic liver or bone marrow failure may occur
in children provoked by fever but without an identifiable
cause. These episodes are usually ascribed to “viral in-
fections.” Considering the episodic encephalopathy with
fever in patients with VWM/CACH, easily mistaken for
“viral encephalitis,” and the recurrent “hepatitis” in pa-
tients with Wolcott-Rallison syndrome, an important
next step is to investigate whether failure of other organs
under fever can be caused by mutations in EIF2B1–
EIF2B5.
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